An investigation into Oscar Health Inc. (NYSE:OSCR)’s technical aspects

After finishing at $3.69 in the prior trading day, Oscar Health Inc. (NYSE: OSCR) closed at $3.51, down -4.88%. In other words, the price has decreased by -$0.1800 from its previous closing price. On the day, 1355101 shares were traded. OSCR stock price reached its highest trading level at $3.6200 during the session, while it also had its lowest trading level at $3.3900.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our goal is to gain a better understanding of OSCR by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.33. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.33.

Upgrades & Downgrades

On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $5.

BofA Securities Downgraded its Neutral to Underperform on June 15, 2022, whereas the target price for the stock was revised from $6 to $4.50.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 when Blackley Richard Scott sold 30,764 shares for $4.88 per share. The transaction valued at 150,156 led to the insider holds 369,521 shares of the business.

Quane Alessandrea C. sold 12,473 shares of OSCR for $60,879 on Mar 06. The EVP, Chief Insurance Officer now owns 188,328 shares after completing the transaction at $4.88 per share. On Mar 02, another insider, Sankaran Sid, who serves as the Interim CFO of the company, sold 110,396 shares for $4.75 each. As a result, the insider received 524,436 and left with 117,452 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.21 while its Price-to-Book (P/B) ratio in mrq is 0.85.

Stock Price History:

Over the past 52 weeks, OSCR has reached a high of $10.52, while it has fallen to a 52-week low of $2.05. The 50-Day Moving Average of the stock is 4.0016, while the 200-Day Moving Average is calculated to be 4.3829.

Shares Statistics:

The stock has traded on average 1.67M shares per day over the past 3-months and 1.46M shares per day over the last 10 days, according to various share statistics. A total of 215.22M shares are outstanding, with a floating share count of 142.34M. Insiders hold about 0.40% of the company’s shares, while institutions hold 88.30% stake in the company. Shares short for OSCR as of Jan 12, 2023 were 7.66M with a Short Ratio of 7.60M, compared to 7.46M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.57% and a Short% of Float of 6.83%.

Earnings Estimates

Its stock is currently analyzed by 4 different market analysts. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.09 and a low estimate of -$0.03, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.19 and low estimates of -$0.33.

Analysts are recommending an EPS of between -$1.51 and -$1.77 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$0.35, with 2 analysts recommending between -$0.1 and -$0.6.

Revenue Estimates

1 analysts predict $1.1B in revenue for the current quarter. It ranges from a high estimate of $1.1B to a low estimate of $1.1B. As of the current estimate, Oscar Health Inc.’s year-ago sales were $972.76M, an estimated increase of 12.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $1.18B, an increase of 15.90% over than the figure of $12.70% in the same quarter last year. There is a high estimate of $1.18B for the next quarter, whereas the lowest estimate is $1.18B.

A total of 3 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $5.46B, while the lowest revenue estimate was $4.34B, resulting in an average revenue estimate of $4.84B. In the same quarter a year ago, actual revenue was $3.96B, up 22.10% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $5.41B in the next fiscal year. The high estimate is $5.98B and the low estimate is $4.84B. The average revenue growth estimate for next year is up 11.80% from the average revenue estimate for this year.